Drugs / Intismeran autogene
Intismeran autogene
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03313778 | Aug 2017 → Nov 2027 expected | cancer | ModernaTX, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06305767 | Mar 2024 → Apr 2027 expected | urinary bladder cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07221474 | Dec 2025 → Jul 2029 expected | non-small cell squamous lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06961006 | May 2025 → Jul 2028 expected | melanoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06833073 | Mar 2025 → Sep 2031 expected | in situ carcinoma, urinary bladder neoplasm | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06307431 | Apr 2024 → Jan 2028 expected | renal cell carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03897881 | Jul 2019 → Nov 2032 expected | melanoma | ModernaTX, Inc. | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06295809 | Apr 2024 → Mar 2026 | skin neoplasm, squamous cell carcinoma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07513376 | May 2026 → Aug 2034 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06623422 | Oct 2024 → May 2033 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06077760 | Dec 2023 → Jun 2030 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT05933577 | Jul 2023 → Oct 2029 expected | melanoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-11-15 | ModernaTX, Inc. | Moderna Announces First-in-Human Dosing for Phase 1 Study (KEYNOTE-603) of mRNA-4157, a Personalized Cancer Vaccine, for the Treatment of Solid Tumors modernatx.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intismeran autogene | “Intismeran autogene (intismeran; formerly V940 or mRNA-4157)” PMID 42223134 ↗ Jun 2026 |
| Known as | intismeran | “Intismeran autogene (intismeran; formerly V940 or mRNA-4157)” PMID 42223134 ↗ Jun 2026 |
| Known as | Intismeran autogen | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068256 ↗ |
| Known as | mRNA-4157 | “Intismeran autogene (also called mRNA-4157) is designed to treat each person's cancer by helping the person's immune system identify and kill cancer cells based on certain...” NCT06305767 ↗3“One trial medicine is intismeran (also called V940/mRNA-4157) and the other is subcutaneous pembrolizumab (also called SC pembrolizumab and MK-3475A).” NCT07513376 ↗ “Intismeran autogene (intismeran; formerly V940 or mRNA-4157)” PMID 42223134 ↗ Jun 2026 |
| Known as | V940 | “One trial medicine is intismeran (also called V940/mRNA-4157) and the other is subcutaneous pembrolizumab (also called SC pembrolizumab and MK-3475A).” NCT07513376 ↗1“Intismeran autogene (intismeran; formerly V940 or mRNA-4157)” PMID 42223134 ↗ Jun 2026 |
| Action | Deplete | “Intismeran autogene (also called mRNA-4157) is designed to treat each person's cancer by helping the person's immune system identify and kill cancer cells based on certain...” NCT06305767 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-based” PMID 42223134 ↗ Jun 2026 |
| Route | Intramuscular | “mRNA-4157 via an intramuscular (IM) injection” NCT03313778 ↗ |